Sinclair Michael 4

Accession 0001385508-21-000119

CIK 0001385508other

Filed

Aug 24, 8:00 PM ET

Accepted

Aug 25, 4:38 PM ET

Size

19.5 KB

Accession

0001385508-21-000119

Form 4

Period: 2021-08-23

Director

Transactions

Exercise/Conversion
Common Stock, par value $0.001 per share
2021-08-25$5.00/sh+50,269$251,345→ 194,339 total
Exercise/Conversion
Common Stock, par value $0.001 per share
2021-08-23$5.00/sh+65,124$325,620→ 209,194 total
Sale
Common Stock, par value $0.001 per share
2021-08-24$15.71/sh−34,607$543,676→ 144,070 total
Exercise/Conversion
Options
2021-08-23−65,124→ 84,876 total
Exercise: $5.00From: 2014-06-15Exp: 2024-06-14→ Common Stock, par value $0.001 per share (65,124 underlying)
Exercise/Conversion
Options
2021-08-25−50,269→ 0 total
Exercise: $5.00From: 2014-06-15Exp: 2024-06-14→ Common Stock, par value $0.001 per share (50,269 underlying)
Sale
Common Stock, par value $0.001 per share
2021-08-23$16.50/sh−65,124$1,074,546→ 144,070 total
Exercise/Conversion
Options
2021-08-24−34,607→ 50,269 total
Exercise: $5.00From: 2014-06-15Exp: 2024-06-14→ Common Stock, par value $0.001 per share (34,607 underlying)
Exercise/Conversion
Common Stock, par value $0.001 per share
2021-08-24$5.00/sh+34,607$173,035→ 178,677 total
Sale
Common Stock, par value $0.001 per share
2021-08-25$14.69/sh−50,269$738,452→ 144,070 total

Footnotes (4)

[F1]This transaction was executed in multiple trades at prices ranging from $16.00 to $17.25. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F2]This transaction was executed in multiple trades at prices ranging from $15.50 to $16.62. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $13.80 to $15.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]These options became exercisable on December 15, 2014 when Opiant Pharmaceuticals entered into a distribution, licensing, royalty, partnership, collaboration, or other significant transaction with respect to the opioid overdose reversal treatment with Adapt Pharma Operations Limited.

Documents

1 file

OPIANT PHARMACEUTICALS, INC.

CIK 0001385508

Entity typeother